Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma
Condition(s):Urinary Bladder Urothelial CarcinomaLast Updated:July 29, 2022Recruiting
Include Studies Not Open or Pending
Condition(s):Urinary Bladder Urothelial CarcinomaLast Updated:July 29, 2022Recruiting
Condition(s):Upper Tract Urothelial Carcinoma Receiving Kidney-sparing TherapyLast Updated:January 12, 2024Recruiting
Condition(s):Metastatic Urothelial CarcinomaLast Updated:June 9, 2023Recruiting
Condition(s):Urothelial CarcinomaLast Updated:November 7, 2023Recruiting
Condition(s):Metastatic Urothelial CarcinomaLast Updated:October 13, 2022Recruiting
Condition(s):Urothelial CarcinomaLast Updated:October 21, 2021Recruiting
Condition(s):Upper Tract Urothelial CarcinomaLast Updated:May 24, 2023Recruiting
Condition(s):Urothelial CarcinomaLast Updated:January 25, 2024Recruiting
Condition(s):Muscle-invasive Urothelial CarcinomaLast Updated:March 22, 2023Not yet recruiting
Condition(s):Carcinoma, Transitional Cell; HER-2 Gene AmplificationLast Updated:April 8, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.